Wockhardt Limited announced its Q3FY26 financial results on February 10, 2026, demonstrating robust performance across key metrics. The pharmaceutical company reported consolidated revenue of Rs 888 crores for the quarter ended December 31, 2025, representing a 23% year-over-year growth from Rs 721 crores in Q3FY24. Net profit after tax surged to Rs 61 crores compared to Rs 20 crores in the corresponding quarter of the previous year.

Consolidated Financial Performance

The company's consolidated results showed strong momentum across all major parameters. Total income reached Rs 913 crores, up from Rs 729 crores in Q3FY24, driven primarily by operational revenue growth.

Standalone Results Show Impressive Turnaround

On a standalone basis, Wockhardt demonstrated even stronger performance with revenue from operations reaching Rs 430 crores in Q3FY26, up 32% from Rs 325 crores in Q3FY24. The company achieved a net profit of Rs 28 crores compared to a loss of Rs 22 crores in the same quarter last year.

Nine-Month Performance Analysis

For the nine months ended December 31, 2025, consolidated revenue reached Rs 2,408 crores compared to Rs 2,269 crores in the corresponding period of FY24. The company reported net profit of Rs 35 crores for the nine-month period, a significant improvement from the loss of Rs 12 crores in the previous year.

Exceptional Items and Strategic Decisions

The company reported exceptional charges of Rs 107 crores for the nine-month period, primarily due to the exit from US generic pharmaceutical business. Wockhardt filed for voluntary liquidation of its US subsidiaries Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC under Chapter 7 of the US Bankruptcy Code on July 11, 2025. Additionally, the company accounted for Rs 10 crores as exceptional items related to the impact of India's new Labour Codes.

Board Meeting and Audit Compliance

The Board of Directors approved the unaudited financial results at their meeting held on February 10, 2026, which commenced at 11:45 a.m. and concluded at 02:15 p.m. The results were reviewed by the Audit Committee and subjected to limited review by M S K C & Associates LLP, the company's statutory auditors.

Source: Wockhardt Limited Q3FY26 Results

Wockhardt Limited has announced successful Phase 3 clinical trial results for its novel intravenous antibiotic Foviscu (WCK 4282), marking a significant milestone in the fight against drug-resistant bacterial infections. The antibiotic successfully met its primary endpoint in treating complicated urinary tract infections (cUTI) and acute pyelonephritis caused by Gram-negative bacteria, including extended-spectrum β-lactamase (ESBL)-producing pathogens.

Phase 3 Trial Results and Clinical Performance

In the randomized, double-blind Phase 3 study, Foviscu demonstrated therapeutic equivalence with meropenem, the gold-standard carbapenem widely used for severe drug-resistant Gram-negative infections. The trial results showed impressive clinical outcomes:

This represents the first Phase 3 head-to-head trial of an antibiotic specifically developed for ESBL infections compared directly with meropenem. The study enrolled 323 hospitalized patients with cUTI and acute pyelonephritis across combined Phase 2 and Phase 3 programs, with Phase 2 including 60 patients and Phase 3 encompassing 263 patients.

Addressing Critical Antimicrobial Resistance

The trial results highlight the urgent need for effective alternatives to combat rising antimicrobial resistance in India. Key findings from the patient population include:

• More than half of Enterobacteriales isolates (51.4%) were ESBL-positive
• 33.8% of Gram-negative bacteria were resistant to cefepime
• Most common causative pathogens included Escherichia coli, Klebsiella spp., Enterobacter spp., and Pseudomonas spp.

ICMR data reveals a high burden of ESBLs and rising resistance to commonly used antibiotics such as piperacillin/tazobactam and cefoperazone/sulbactam. This resistance pattern increasingly forces clinicians to rely on carbapenems like meropenem, thereby accelerating carbapenem resistance. Currently, approximately 65 lakh treatment courses of meropenem, piperacillin/tazobactam, and cefoperazone/sulbactam are used annually in India.

Foviscu's Unique Formulation and Development

Foviscu represents a breakthrough as the globally only scientifically developed single-vial dosage form that combines pharmacodynamically optimized and clinically validated doses of tazobactam 2 g and cefepime 2 g. This combination is enabled by proprietary technology designed to ensure safety and efficacy.

The antibiotic has undergone extensive global evaluation through a comprehensive program covering:

• Clinical development across multiple countries
• Pharmacokinetics/pharmacodynamics (PK/PD) studies
• Antimicrobial susceptibility testing methods
• Microbiology studies on global bacterial isolates

Phase 1 and renal impairment studies were conducted in The Netherlands, PK/PD studies in the US, Europe and India, and microbiology studies on global bacterial isolates in the US and India.

Strengthening Wockhardt's Antibiotic Portfolio

With this Phase 3 success, Foviscu becomes the fifth proprietary antibiotic from Wockhardt to complete a registration-enabling Phase 3 study. The company's antibiotic portfolio now includes:

This achievement further strengthens Wockhardt's leadership in antibiotic discovery, with the company maintaining focus on discovering novel medicines for multi-drug resistant infections for over 25 years. All six products in Wockhardt's drug discovery portfolio at various stages of clinical development and commercialization have been granted Qualified Infectious Disease Product (QIDP) status by the US FDA, including WCK 4282.

Regulatory Support and Future Implications

The combined Phase 2/3 trial received partial support from the National Biopharma Mission (NBM), an initiative of the Department of Biotechnology, Government of India. Foviscu's strong activity against ESBL-producing pathogens has been documented in several peer-reviewed publications in leading international journals.

By providing an effective alternative to carbapenems, Foviscu has the potential to reduce carbapenem use and strengthen antibiotic stewardship efforts to curb antimicrobial resistance. This development represents a crucial step forward in addressing the growing challenge of drug-resistant bacterial infections, particularly in healthcare settings where ESBL prevalence remains high.